Health

STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 06:36:26 UTC.

Briefings

A Bristol Myers Squibb Phase 1 trial involving a CAR-T therapy for multiple sclerosis resulted in a patient death due to septic pneumonia, complicating safety assessments. Simultaneously, a Roche drug named divarasib showed improved survival in late-stage non-small cell lung cancer compared to other treatments. The evidence highlights distinct safety risks in autoimmune trials and potential efficacy gains in specific cancer subtypes.

Key points

• A patient died after receiving a CAR-T therapy in a Phase 1 trial for multiple sclerosis, experiencing septic pneumonia that did not resolve with standard treatments.
• A Roche drug called divarasib improved survival in late-stage non-small cell lung cancer compared to similar drugs from Amgen and Bristol Myers Squibb.

Context

The findings from the Bristol Myers Squibb trial and the Roche divarasib study provide critical data on safety and efficacy for autoimmune and cancer therapies, influencing future clinical trial designs and treatment options.

Limitations

The Bristol trial data is from a Phase 1 study with a single death, limiting generalizability. The Roche study is a late-stage study with limited patient numbers and may not reflect long-term outcomes. No causal link between the CAR-T therapy and death is confirmed due to prior complications.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 07:52:25 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiaijc2iagnxjjxfvndrz6ik44oj2mj5mwovavabmkvb2ljkmxpm2u